Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance
- PMID: 3922650
Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance
Abstract
We determined the urinary excretion of 5-fluorouracil (5FU) and its metabolites during six days of chemotherapy, using the non-invasive approach of 19F nuclear magnetic resonance. With this method, which requires no labeled drug, one can study the biological sample directly and simultaneously identify and quantify all the fluorinated metabolites. The daily urinary excretion of 5FU and its metabolites was high (94.8% of 5FU administered) and nearly constant all during the treatment. By far the major excreted catabolite was alpha-fluoro-beta-alanine, which made up 78.9% of the total. Unchanged 5FU (10.8% of dose injected) was found only during the first 2 h after injection. We observed neither accumulation of 5FU nor modifications in its metabolism during the treatment.
Similar articles
-
Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry.Cancer Res. 1986 Apr;46(4 Pt 2):2105-12. Cancer Res. 1986. PMID: 2936452
-
pH dependence of 5-fluorouracil uptake observed by in vivo 31P and 19F nuclear magnetic resonance spectroscopy.Cancer Res. 1991 Oct 15;51(20):5770-3. Cancer Res. 1991. PMID: 1913695
-
Proton-decoupled 19F spectroscopy of 5-FU catabolites in human liver.Magn Reson Med. 1997 Mar;37(3):321-6. doi: 10.1002/mrm.1910370302. Magn Reson Med. 1997. PMID: 9055218
-
Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs.Clin Chim Acta. 2006 Apr;366(1-2):61-73. doi: 10.1016/j.cca.2005.10.013. Epub 2005 Dec 6. Clin Chim Acta. 2006. PMID: 16337167 Review.
-
Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs.Curr Drug Metab. 2000 Nov;1(3):271-303. doi: 10.2174/1389200003339036. Curr Drug Metab. 2000. PMID: 11465049 Review.
Cited by
-
Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.Drugs Aging. 1991 Jul-Aug;1(4):317-37. doi: 10.2165/00002512-199101040-00007. Drugs Aging. 1991. PMID: 1794023 Review.
-
Mass balance studies, with a focus on anticancer drugs.Clin Pharmacokinet. 2006;45(1):33-58. doi: 10.2165/00003088-200645010-00003. Clin Pharmacokinet. 2006. PMID: 16430310 Review.
-
Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.Invest New Drugs. 1987;5(3):273-9. doi: 10.1007/BF00175298. Invest New Drugs. 1987. PMID: 2959633
-
Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.J Pharm Sci. 2018 Feb;107(2):513-528. doi: 10.1016/j.xphs.2017.10.012. Epub 2017 Oct 16. J Pharm Sci. 2018. PMID: 29045885 Free PMC article. Review.
-
5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.Br J Cancer. 1997;76(9):1170-80. doi: 10.1038/bjc.1997.529. Br J Cancer. 1997. PMID: 9365165 Free PMC article.